Small Research Grant Program for the Next Generation of Clinical Researchers in AD/ADRD Research: Area of Focus Systems Biology (R03 Clinical Trial Not Allowed)
This Small Research Grant Program (R03) will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.
Funding Agency: NIH
Deadline: November 16, 2022
Amount: $100,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAS-19-393.html
Small Research Grant Program for the Next Generation of Clinical Researchers in AD/ADRD Research: Area of Focus Basic Science (R03 Clinical Trials Not Allowed)
This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.
Funding Agency: NIH
Deadline: November 16, 2022
Amount: $100,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAS-19-392.html
Small Research Grant Program for the Next Generation of Clinical Researchers in AD/ADRD Research: Area of Focus Archiving and Leveraging Existing Data Sets for Analyses (R03 Clinical Trial Not Allowed)
This Small Research Grant (R03) will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging, and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.
Funding Agency: NIH
Deadline: November 16, 2022
Amount: $100,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAS-19-391.html
Pediatric HIV/AIDS Cohort Study (PHACS) 2020 (P01 Clinical Trial Not Allowed)
The purpose of this FOA is to continue support for the Pediatric HIV/AIDS Cohort Study (PHACS) which addresses the clinical course of perinatally acquired HIV infection in adolescents and young adults and the oral and systemic health consequences of in utero and infant exposure to antiretroviral therapy in cohorts of children in the United States.
Funding Agency: NIH
Deadline: December 5, 2019
Amount: $12,000,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-20-002.html
Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention. Applications may propose treatment or prevention products delivered using sustained release platforms (oral, injection, implant or direct delivery to HIV target mucosa) that will provide a minimum of 1 week for oral (treatment) or a minimum of once a month for all other drug delivery systems for prevention and treatment.
Funding Agency: NIH
Deadline: January 7, 2022
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-029.html
Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clinical Trial Not Allowed)
This initiative will support basic and translational research to address knowledge gaps that hinder the development and regulation of bacteriophage used to prevent and treat drug-resistant bacterial infections.
Funding Agency: NIH
Deadline: March 18, 2020
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-065.html
Medication Safety: Advancing the Development of Improvement Strategies and Tools (R18)
This funding opportunity continues AHRQ’s support of medication safety investigator-initiated research projects. Medication safety research should not only address the prevention of harm, but also promote standardized and optimized practices and behaviors.
Funding Agency: Agency for Health Care Research and Quality
Deadline: September 25, 2022
For more information: Go to grants.gov and search opportunity # PA-20-028